[Course and treatment of progressive subacute encephalopathy caused by human immunodeficiency virus in children. The value of Botulinum toxin]

Rev Neurol. 2004 Feb;38(3):239-43.
[Article in Spanish]

Abstract

Introduction: Progressive subacute encephalopathy due to human immunodeficiency virus (PSE-HIV) is an important cause of morbidity and mortality in perinatal HIV infection. Although current combined antiretroviral therapies do manage to check its progression, they often give rise to severe motor sequelae that are similar to the spastic infantile cerebral palsy resulting from other aetiologies. We present the case reports of four preschool age children suffering from this pathology who have benefited from long term treatment with botulinum toxin type A (BTA).

Case reports: Four patients suffering from early onset PSE HIV, who responded well to combined antiviral therapies, and who had severe motor sequelae (two cases of tetraparesis and two spastic dysplegias), with no cognitive disorders. The multidisciplinary treatment of their motor disorder included six monthly sessions of muscular injections of BTA in the usual doses, with good results from the functional point of view and with no significant side effects.

Discussion: PSE-HIV is defined by one of the following criteria: acquired microcephalus, retarded neurological development or symmetrical motor involvement. It constitutes one of the most frequent diagnostic criteria of AIDS in patients infected by vertical transmission. An early diagnosis and treatment are fundamental for the patient's prognosis. Severe motor sequelae in the form of spastic infantile cerebral palsy are frequent. In our experience treatment of the spasticity associated to this entity with BTA has proved to be useful and safe, with a clear improvement in gait functionality.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • AIDS Dementia Complex / complications*
  • AIDS Dementia Complex / drug therapy
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Botulinum Toxins, Type A / therapeutic use*
  • Cerebral Palsy / drug therapy
  • Cerebral Palsy / etiology*
  • Disease Progression
  • Drug Evaluation
  • Female
  • Gait Disorders, Neurologic / drug therapy
  • Gait Disorders, Neurologic / etiology
  • Gait Disorders, Neurologic / therapy
  • HIV Infections / transmission
  • Humans
  • Infant
  • Infectious Disease Transmission, Vertical
  • Male
  • Muscle Spasticity / drug therapy
  • Muscle Spasticity / etiology*
  • Orthotic Devices
  • Physical Therapy Modalities
  • Quadriplegia / drug therapy
  • Quadriplegia / etiology*

Substances

  • Anti-HIV Agents
  • Botulinum Toxins, Type A